Dependence of cytokinemia on the clinical course of chronic obstructive pulmonary disease combined with hypertension.

Authors

  • V.A A. Kapustnyk
  • I. F. Kostyuk
  • A. Ya. Melenevych

DOI:

https://doi.org/10.26641/2307-0404.2018.3.147953

Keywords:

chronic obstructive pulmonary disease, hypertension, systemic inflammation, biomarkers, interleukin-18, interleukin-10

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease. The prevalence of COPD continues to increase steadily. 90% of patients with COPD have at least one comorbid pathology. Among concomitant COPD diseases pathologies of the cardiovascular system prevail. The variety of the disease course in patients is the basis for distinguishing COPD patients with similar pathophysiological mechanisms based on analysis of biomarkers. The aim of the study was to analyze the dependence of cytokinemia (interleukin-18 and interleukin-10) on the clinical course of the disease in patients with COPD in combination with hypertension (HT). In total, 100 occupational COPD (GOLD 2, group B) patients in remission were monitored. The main group included 69 patients with COPD in combination with HT stage II, the comparison group - 31 patients with isolated COPD, and the control group - 20 healthy volunteers. All groups were comparable by sex and age. Levels of interleukin-18 (IL-18) and interleukin-10 (IL-10) were significantly higher in COPD patients combined with HT compared to healthy volunteers and isolated COPD. Growth of IL-18/IL-10 ratio is associated with increase in the degree of dyspnea, decrease in exercise tolerance, increase in desaturation during the 6-min walk test, decrease in body mass index, waist and mid-upper arm circumferences, and also more frequent detection of emphysematous changes in chest X-ray. Thus, the IL-18/IL-10 ratio reflects the state of the immune-inflammatory process and has the potential to predict the future risk of developing irreversible pathological changes in the respiratory tract, alveoli and lung vessels with the formation of emphysematous and fibrotic changes.

Author Biographies

V.A A. Kapustnyk

Kharkiv national medical university
Department of internal and occupational diseases
Trinkler str., 6, Kharkiv, 61022, Ukraine

I. F. Kostyuk

Kharkiv national medical university
Department of internal and occupational diseases
Trinkler str., 6, Kharkiv, 61022, Ukraine

A. Ya. Melenevych

Kharkiv national medical university
Department of internal and occupational diseases
Trinkler str., 6, Kharkiv, 61022, Ukraine

References

Makarevich AE. [To the problem of clinical phenotypes of chronic obstructive pulmonary disease]. Praktikuyuchiy líkar. 2016;3:57-67. Ukrainian.

Agusti A. What does endotyping mean for treat­ment in chronic obstructive pulmonary disease? Lancet. 2017;390(10098):980-7.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) The Global Strategy for tre Diagnosis, Management, and Prevention of Chronic Obstructive Pul­monary Disease (2018 report). [Internet]. Available from: http://www.goldcopd.org

Kang MJ, Choi JM, Kim BH, Lee CM, Cho WK, Choe G, Kim DH, Lee CG, Elias JA. IL-18 induces emphysema and airway and vascular remodeling viaIFN-γ,IL-17A, and IL-13. Am. J. Respir. Crit. Care Med. 2012;185(11):1205-17.

Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients. Medicine (Baltimore). 2017;96(19):e6836. doi: 10.1097/MD.0000000000006836

Russell DW, Wells JM, Blalock JE. Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype. Curr. Opin. Pulm. Med. 2016;22(2):91-99.

Downloads

How to Cite

1.
Kapustnyk VA, Kostyuk IF, Melenevych AY. Dependence of cytokinemia on the clinical course of chronic obstructive pulmonary disease combined with hypertension. Med. perspekt. [Internet]. 2018Nov.29 [cited 2024Nov.22];23(3):41-6. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/147953

Issue

Vol. 23 No. 3 (2018)

Section

CLINICAL MEDICINE

License

Copyright (c) 2018 Medicni perspektivi (Medical perspectives)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.

Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.